Kanser hastalığı, sinsi bir hastalıktır.. Pat diye çıkabilir.. Özellikle de akciğer kanseri.. Akciğer kanserinin erken tanısı için güçlü bir tarama tetkiki yoktur.. Ama belli bir düzeyin üzerinde sigara içen bireyleri 55 yaşının üzerinde tomografiyle taramak istiyoruz.. Erken olarak yakalanırsa, cerrahi müdahale yapılabiliyor. Meme kanseri erken tanısı için mamografi, kalın barsak kanseri erken tanısı için kolonoskopi…
Meme kanseri, prostat kanseri ve jinekolojik kanserlerin tedavilerinde hormon tedavileri uygulanabiliyor. Pandemi döneminde de aksatılmaması gereken hormon tedavisini alınırken yan etki tedavilerinin ihmal edilmemesi gerektiğini belirten Anadolu Sağlık Merkezi Medikal Onkoloji Uzmanı Prof. Dr. Serdar Turhal, “Eğer bir kanser hücresinin çoğalmasında hormonların etkisi varsa (prostat kanseri, meme kanseri, jinekolojik kanserler) hormon tedavileri ya da anti…
Obesity is a well-known carcinogenic factor for colorectal cancer [1, 2]. However, the relationship between obesity and malignancy is still not well understood. Obesity can cause production of VEGF, angiopoietin-2, and other growth factors that induce tumor growth [3, 4]. It can also cause insulin resistance, hyperinsulinemia, and increased production of adipokines and proinflamatory cytokines…
Hepatocellular carcinoma (HCC) is the fifth most common cancer amongman and seventh among woman and ranked as the third most common cause of cancer-related deaths [1, 2]. Chronic liver injury, Hepatitis B (HBV) and C (HCV) virus infections, alcohol-associated diseases, and aflatoxin intoxications are the leading causes of HCC development. Several mutations affecting WNT/𝛽-Catenin, PI3K/RAS,…
Efforts to improve outcomes beyond those achieved with 1 year of trastuzumab in patients with early-stage HER2-positive breast cancer are ongoing. Several different approaches, including extending the duration of trastuzumab to 2 years (HERceptin Adjuvant [HERA] trial),5 concurrent or sequential administration of lapatinib, a tyrosine kinase inhibitor, with trastuzumab (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation…
Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers.1 On admission, one-third of patients with RCC are at the metastatic stage.2 Chemotherapy resistance is very high in patients with RCC.3 Only a limited subset of patients ( 20%) benefit from cytokine therapy.4-7 It has been shown that the median progressionfree survival (PFS) was…
